Invectys will attend the Sachs Forum in Zürich, 6. March – 7. March 2017 Meet Invectys there ! More information: invest@invectys.com The 10th…
J.P. Morgan 35Th Annual Healthcare Conference 2017 San-Francisco…
Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer…
With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy Paris,…
Invectys files a patent on the acquisition of antibodies against an immune checkpoint expressed in all types of cancers and strengthens its HLA-G intellectual property…
With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance. Invectys announces fundraising of an additional…
Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine A new clinical hope in cancer…
Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises,…
